Aptevo Therapeutics Inc.
APVO
$4.30
-$0.48-10.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -70.66% | 38.94% | -62.24% | -56.25% | -94.19% |
| Gross Profit | 70.66% | -38.94% | 62.24% | 56.25% | 94.19% |
| SG&A Expenses | -11.88% | -10.42% | -21.09% | -12.33% | -9.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.20% | -0.03% | -20.55% | -26.34% | -9.97% |
| Operating Income | 7.20% | 0.03% | 20.55% | 26.34% | 9.97% |
| Income Before Tax | 6.23% | -1.87% | 19.47% | 25.98% | -474.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.23% | -1.87% | 19.47% | 25.98% | -474.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.23% | -6.93% | 19.47% | 25.98% | -346.45% |
| EBIT | 7.20% | 0.03% | 20.55% | 26.34% | 9.97% |
| EBITDA | 6.66% | -0.69% | 20.33% | 26.10% | 9.25% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |